Outlook Wealth Advisors LLC Buys 145 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Outlook Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 852 shares of the company’s stock after purchasing an additional 145 shares during the period. Outlook Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $352,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its position in IDEXX Laboratories by 13.1% in the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock worth $249,855,000 after purchasing an additional 59,519 shares during the last quarter. Citizens Financial Group Inc. RI lifted its stake in shares of IDEXX Laboratories by 47.1% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 675 shares of the company’s stock worth $329,000 after purchasing an additional 216 shares during the period. Axxcess Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 19.4% in the second quarter. Axxcess Wealth Management LLC now owns 2,859 shares of the company’s stock worth $1,393,000 after buying an additional 464 shares during the last quarter. Wealth Alliance grew its holdings in IDEXX Laboratories by 9.5% during the second quarter. Wealth Alliance now owns 460 shares of the company’s stock valued at $224,000 after purchasing an additional 40 shares during the period. Finally, Mercer Global Advisors Inc. ADV increased its position in IDEXX Laboratories by 4.3% in the second quarter. Mercer Global Advisors Inc. ADV now owns 4,295 shares of the company’s stock worth $2,039,000 after buying an additional 176 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $428.62 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The company has a 50 day moving average price of $423.97 and a 200-day moving average price of $458.74. The firm has a market cap of $35.10 billion, a price-to-earnings ratio of 41.33, a price-to-earnings-growth ratio of 3.52 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same quarter last year, the business earned $2.53 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Insider Activity at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.18% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler restated a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $539.63.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.